Showing results (81-90 of 101) with videos related to
Sort By:
Pageof 11
Journal of Clinical Microbiology|July 14, 2017
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 StrainsLavinia Fabeni, Giulia Berno, Joseph Fokam, et al.Plos One|January 24, 2013
The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencingValentina Svicher, Valeria Cento, Gabriella Rozera, et al.Journal of the International AIDS Society|November 15, 2014
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trialMassimiliano Fabbiani, Simona Di Giambenedetto, Eugenia Quiros-Roldan, et al.BMJ Open|December 5, 2019
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)Arturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, et al.The Journal of Antimicrobial Chemotherapy|January 18, 2017
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, et al.Plos One|August 26, 2014
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAARTDaniele Armenia, Cathia Soulie, Domenico Di Carlo, et al.Journal of Clinical Medicine|December 11, 2025
Low Prevalence of HCV Infection Among MSM in an Intervention for HCV Micro-Elimination in Rome Urges a Focus on High-Risk BehavioursPierluca Piselli, Massimo Giuliani, Massimo Farinella, et al.Frontiers in Immunology|March 1, 2019
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up StudyCecilia Sgadari, Paolo Monini, Antonella Tripiciano, et al.The Journal of Antimicrobial Chemotherapy|April 19, 2018
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli, et al.Ebiomedicine|April 11, 2021
Anti-Tat immunity defines CD4<sup>+</sup> T-cell dynamics in people living with HIV on long-term cARTAntonella Tripiciano, Orietta Picconi, Sonia Moretti, et al.Pageof 11